002693.SZ
双成药业
SZSE · Healthcare · C 制造业 · CN
CNY 8.90
−5.42%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 288.5M | 276.8M | 174.2M | 235.9M | 274.8M |
| Cost of Revenue | 125.0M | 125.2M | 76.6M | 74.9M | 88.3M |
| Gross Profit | 163.5M | 151.5M | 97.6M | 161.1M | 186.5M |
| Operating Expenses | |||||
| R&D Expense | 9.2M | 8.1M | 12.9M | 8.0M | 14.6M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 84.9M | 85.1M | 99.7M | 76.3M | 81.2M |
| Selling & Marketing Expense | 26.5M | 30.5M | 50.8M | 103.0M | 126.2M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 141.4M | 142.4M | 178.0M | 203.3M | 240.9M |
| Cost and Expenses | 266.4M | 267.6M | 254.6M | 278.2M | 329.2M |
| Operating Income (EBIT) | 21.8M | 8.9M | (106.1M) | (73.2M) | (9.0M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 21.1M | 8.2M | (106.2M) | (73.0M) | (8.9M) |
| Income Tax Expense | (492.1K) | (764.4K) | 97.3K | (991.6K) | (385.0K) |
| Bottom Line | |||||
| Net Income | 32.5M | 19.0M | (78.3M) | (50.7M) | 9.0M |
| Earnings from Cont. Ops | 21.8M | 8.9M | (106.3M) | (72.0M) | (8.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 32.5M | 19.0M | (78.3M) | (50.7M) | 9.0M |
| Per Share | |||||
| Basic EPS | CN¥0.08 | CN¥0.05 | (CN¥0.19) | (CN¥0.12) | CN¥0.02 |
| Diluted EPS | CN¥0.08 | CN¥0.05 | (CN¥0.19) | (CN¥0.12) | CN¥0.02 |
| Revenue Per Share | CN¥0.69 | CN¥0.73 | CN¥0.42 | CN¥0.56 | CN¥0.61 |
| Shares | |||||
| Basic Shares Outstanding | 415.4M | 380.9M | 412.1M | 422.8M | 450.6M |
| Diluted Shares Outstanding | 415.4M | 380.9M | 412.1M | 422.8M | 450.6M |
| Profitability Metrics | |||||
| EBITDA | — | 64.0M | (50.7M) | (19.1M) | 49.5M |
| D&A | — | 55.1M | 55.5M | 54.0M | 58.5M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026